Please login to read the full article.
Scrip Regulatory Affairs
EMA plans to revise current guidance on quality issues for biosimilars
02 March 2011
Vibha Sharma
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- EU finalises guidance on reporting adverse events from clinical trials
- ICH allows first non-ICH regulators into QSE working groups; guidelines progress announced
- India consults on draft guideline for approving clinical trials and new drugs
- US FDA consults on human factors testing guidance to improve device safety
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
FEATURES
Regulatory Affairs Pharma Features
COMMENT
Other Informa Comments
